AF 13948

Drug Profile

AF 13948

Latest Information Update: 18 Jul 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Peptides
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombocytopenia

Most Recent Events

  • 18 Jul 2001 Investigation in Thrombocytopenia in USA (Unknown route)
  • 19 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
  • 21 Oct 1998 Glaxo Wellcome confirms that AF 13948 is a prototype and not intended for therapeutic applications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top